What it's for (Indications)
- Lercanidipine, marketed under brand names such as Leradip, is a dihydropyridine calcium channel blocker specifically indicated for the treatment of essential hypertension.
- It is utilized as a monotherapy or in combination with other antihypertensive agents to effectively reduce elevated blood pressure.
- Its primary role is in the management of sustained systemic hypertension in adult patients, helping to decrease the risk of cardiovascular events associated with chronic high blood pressure.
- The controlled-release formulation allows for once-daily dosing, which contributes to patient adherence and consistent blood pressure control throughout the 24-hour period.
- It is important to note that the efficacy and safety of lercanidipine for indications other than essential hypertension have not been established in clinical trials.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended starting dose for lercanidipine is 10 mg once daily, administered orally at least 15 minutes before a meal, as food intake significantly increases its systemic bioavailability. The optimal time for administration is in the morning. The dosage can be increased to 20 mg once daily after a minimum of two weeks, depending on the patient's individual response to treatment and the blood pressure control achieved. Doses exceeding 20 mg daily are generally not recommended due to limited additional efficacy and a potential increase in dose-related adverse effects. For elderly patients and those with mild to moderate hepatic or renal impairment, caution is advised, and dose adjustments may be necessary, typically starting with 10 mg daily and carefully monitoring the patient's response and tolerability. In severe hepatic or renal impairment, its use is generally contraindicated. |
Safety & Warnings
Common Side Effects
- Lercanidipine is generally well-tolerated, but like all medications, it can cause adverse effects.
- Common side effects, typical of dihydropyridine calcium channel blockers, include headache, flushing, peripheral edema (swelling of ankles and feet, particularly dose-related), and dizziness.
- Other frequently reported adverse reactions may include palpitations, tachycardia, fatigue, and gastrointestinal disturbances such as nausea, dyspepsia, or diarrhea.
- Less common but potentially serious side effects can involve syncope, excessive hypotension, and in rare instances, exacerbation of angina pectoris, particularly at the initiation of treatment or following dose increases in susceptible individuals.
- Patients should be advised to report any persistent or bothersome side effects, or any new or worsening symptoms, to their healthcare provider for evaluation, as some may require medical attention or dosage adjustment.
Serious Warnings
- Black Box Warning: **Serious Warnings** Lercanidipine does not carry an FDA-mandated Black Box Warning. However, healthcare professionals and patients should be aware of several serious safety considerations. There is a potential for significant and symptomatic hypotension, particularly upon initiation of therapy or with dose increases, which may lead to syncope or other adverse cardiovascular events. Patients with pre-existing conditions such as heart failure or angina pectoris should be closely monitored, as, in rare instances, calcium channel blockers can worsen angina or precipitate acute myocardial infarction, especially with rapid titration or in susceptible individuals. Concurrent use of lercanidipine with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin) or cyclosporine is strictly contraindicated due to a substantial increase in lercanidipine plasma concentrations, which can dramatically enhance its hypotensive effects and the risk of other adverse reactions. Furthermore, patients should be advised to avoid grapefruit juice, as it can also significantly elevate lercanidipine levels. Careful patient selection and dosage titration are crucial to minimize these risks and ensure safe and effective treatment.
- Serious warnings associated with lercanidipine include the potential for excessive hypotension, especially during initiation of therapy or dose titration, which can lead to syncope or cerebrovascular events.
- Caution is advised in patients with pre-existing heart failure, as negative inotropic effects, though minimal with lercanidipine at therapeutic doses, could theoretically worsen cardiac function in severe cases.
- Similarly, in patients with angina pectoris, particularly unstable angina, the drug should be used with extreme caution as, in rare cases, calcium channel blockers can paradoxically increase the frequency, duration, or severity of angina, or even precipitate acute myocardial infarction upon initiation or dose increase.
- The concomitant use of strong CYP3A4 inhibitors (e.
- g.
- , ketoconazole, itraconazole, clarithromycin, erythromycin, ritonavir) or grapefruit juice is strongly discouraged due to significant increases in lercanidipine plasma levels, leading to enhanced pharmacological effects and an increased risk of dose-dependent adverse reactions.
- Patients with severe hepatic or renal impairment should avoid lercanidipine.
- Furthermore, its safety and efficacy in pediatric populations have not been established.
How it Works (Mechanism of Action)
Lercanidipine is a third-generation dihydropyridine calcium channel blocker with high lipophilicity and pronounced vascular selectivity. Its primary mechanism of action involves the inhibition of the transmembrane influx of extracellular calcium ions through the L-type voltage-dependent calcium channels present in vascular smooth muscle cells. This inhibition leads to a reduction in intracellular calcium concentrations within these cells, resulting in dose-dependent peripheral vasodilation. The relaxation of arterial smooth muscle reduces systemic vascular resistance and, consequently, lowers arterial blood pressure. Lercanidipine exhibits minimal direct effects on myocardial contractility or atrioventricular conduction at therapeutic doses, making its hypotensive effects predominantly mediated by peripheral vasodilation. The slow onset and prolonged duration of action, attributable to its high lipophilicity and membrane partitioning, contribute to its effectiveness as a once-daily antihypertensive agent with sustained blood pressure control.
Commercial Brands (Alternatives)
No other brands found for this formula.